Centre Hospitalier Universitaire de Liège (CHU Liège)

Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib (RIB) plus fulvestrant (FUL) as first-line (1L) and second-line (2L) therapy in MONALEESA-3 (ML-3) (2020) Fasching P, Neven P, Jerusalem G, Beck JT, Chan A, De Laurentiis M, Bianchi GV, et al. Conference contribution Quality-adjusted survival with ribociclib plus fulvestrant (R plus F) versus placebo plus fulvestrant (P plus F) in postmenopausal women (PMW) HR+/HER2-advanced breast cancer (ABC) based on the MONALEESA-3 trial (2020) Jerusalem G, Delea T, Martin Jimenez M, De Laurentiis M, Nusch A, Beck JT, Chan A, et al. Conference contribution Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer (2020) Slamon DJ, Neven P, Chia S, Fasching P, De Laurentiis M, Im SA, Petrakova K, et al. Journal article Genetic and phenotypic spectrum associated with IFIH1 gain-of-function (2020) Rice G, Park S, Gavazzi F, Adang LA, Ayuk LA, Van Eyck L, Seabra L, et al. Journal article Update on the ESCEO recommendation for the conduct of clinical trials for drugs aiming at the treatment of sarcopenia in older adults (2020) Reginster JY, Beaudart C, Al-Daghri N, Avouac B, Bauer J, Bere N, Bruyère O, et al. Journal article, Review article Inherited CDH1 pathogenic variant: is there a place for surveillance of esophageal gastric inlet patch? (2020) Leclercq P, Jadot V, Bours V, Oliveira C, Neumann H, Bisschops R Journal article Repeated kidney re-transplantation—the Eurotransplant experience: a retrospective multicenter outcome analysis (2020) Assfalg V, Selig K, Tolksdorf J, Van Meel M, De Vries E, Ramsoebhag AM, Rahmel A, et al. Journal article Early Symptom Improvement With Risankizumab Treatment in Patients With Moderately to Severely Active Crohn's Disease: Analysis From a Phase 2 Study (2019) Feagan BG, Sandborn WJ, D'Haens GR, Panes J, Kaser A, Ferrante M, Louis E, et al. Conference contribution Overall survival (OS) results of the phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor 2-negative (HER2-) advanced breast cancer (ABC) treated with fulvestrant (FUL) (+) ribociclib (RIB) (2019) Slamon DJ, Neven P, Chia S, Fasching P, De Laurentiis M, Im SA, Petrakova K, et al. Conference contribution Multimodality imaging in cardiology: a statement on behalf of the Task Force on Multimodality Imaging of the European Association of Cardiovascular Imaging (2019) Fox K, Achenbach S, Bax J, Cosyns B, Delgado V, Dweck MR, Edvardsen T, et al. Journal article